hummm,,,,for those with a statistics background and those who have the science backgound what is the statistical significance of increasing the required # of events which is again a % of the total patient # for the FA? Does it possibly increase or imply greater ability for the DSMB and the CSC to analyse the data and ultimately be more meaningful around the end points in the BoM trial? Or is it just the fact that the FDA want the numbers in the trial increased with the US involvement which is over and above the previous defined patient trial numbers.,,its all gobbly gook to a hayseed like me!,,,,,me got the thinking man syndrome here,,,,,,,,,,,!